Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma
Journal of Clinical Oncology · 20.07.2025 · 43 (21) · 2398-2408
DOI: 10.1200/jco-25-00759 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.07.2025. Verfasst von Dan P Zandberg und 18 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA. Hauptthemen laut MEDLINE: Cetuximab, Antibodies, Monoclonal, Humanized, Carcinoma, Squamous Cell, Skin Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Continued improvement in outcomes is needed for advanced cutaneous squamous cell carcinoma (cSCC). Methods Alliance A091802 is a randomized phase II trial of avelumab (800 mg IV once every 2 weeks) plus cetuximab (500 mg/m 2 IV once every 2 weeks) versus avelumab alone once every 2 weeks for up to 2 years. Cetuximab was given for 1 year in the avelumab + cetuximab arm. Crossover at progression to avelumab + cetuximab was allowed. Randomization was 1:1, stratified by PD-L1 and HIV status. Patients had distant metastatic or unresectable locally advanced cSCC, were anti–PD-1/PD-L1 monoclonal antibody–naive, had no previous cetuximab in the advanced setting, had an Eastern Cooperative Oncology Group performance status of 0-2, and could be HIV+ (CD4 >200, viral load
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA.
- Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN.
- Department of Medicine, University of Chicago, Chicago, IL.
- MUSC Hollings Cancer Center, Charleston, SC.
- University of Michigan Rogel Cancer Center, Ann Arbor, MI.
- University of Arizona Cancer Center, Tucson, AZ.
ORCID-Profile: Dan P Zandberg, Ari J Rosenberg, Paul Swiecicki, Andrew S Poklepovic, Jessica R Bauman, Nabil F Saba, Diwakar Davar, Alan L Ho, Stephanie A Berg, Gary K Schwartz
Förderung
- NCI NIH HHS
Zitieren
APA
Zandberg, D. P., Allred, J. B., Rosenberg, A. J., Kaczmar, J. M., Swiecicki, P., Julian, R. A., Poklepovic, A. S., Bauman, J. R., Phan, M. D., Saba, N. F., Rivera, E., Rowland, K., Davar, D., Cordes, J., Ho, A. L., Zhang, M., Berg, S. A., Munster, P. N., & Schwartz, G. K. (2025). Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma. Journal of Clinical Oncology, 43(21), 2398-2408. https://doi.org/10.1200/jco-25-00759
Vancouver
Zandberg DP, Allred JB, Rosenberg AJ, Kaczmar JM, Swiecicki P, Julian RA, et al. Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma. Journal of Clinical Oncology. 2025;43(21):2398-2408. doi:10.1200/jco-25-00759
BibTeX
@article{Zandberg2025,
author = {Zandberg, Dan P and Allred, Jacob B and Rosenberg, Ari J and Kaczmar, John M and Swiecicki, Paul and Julian, Ricklie A and Poklepovic, Andrew S and Bauman, Jessica R and Phan, Minh D and Saba, Nabil F and Rivera, Edgardo and Rowland, Kendrith and Davar, Diwakar and Cordes, Julia and Ho, Alan L and Zhang, Miao and Berg, Stephanie A and Munster, Pamela N and Schwartz, Gary K},
title = {Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {21},
pages = {2398--2408},
doi = {10.1200/jco-25-00759}
}
EUVIMED